SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending as investors debate the impact of potential regulatory interest rate caps alongside the company's aggressive pivot toward blockchain and AI-driven payment solutions. The community is actively weighing the stock's long-term compounding potential against near-term headwinds from proposed fee legislation and shifting global payment standards.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

ChainLink is seeing increased community chatter as it remains a central pillar in institutional RWA tokenization, with investors weighing its long-term infrastructure utility against ongoing frustration with its lagging price performance. While proponents point to growing adoption by major financial institutions and the potential for a breakthrough with upcoming regulatory clarity, others are increasingly vocal about the token's stagnant price action and underwhelming historical returns.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is seeing significant investor interest and high volatility following unprecedented Phase 3 data for its pancreatic cancer treatment, daraxonrasib, which significantly extended median overall survival and reduced mortality risk. The community is actively discussing the potential for a massive bidding war among big pharma suitors as they look to replace revenue from aging blockbuster drugs, alongside analysis of the company's recent large-scale equity offering and upcoming data presentations at the AACR annual meeting.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining traction as community members highlight its role in providing high-speed data feeds for real-world assets and major institutional partners. Enthusiasts are actively debating the network's shift toward a paid service model and its potential as a critical infrastructure layer alongside established oracle competitors.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as investors digest reports of potential takeover interest from Apollo-backed Legendary Entertainment. The community is closely monitoring M&A speculation, with many highlighting the studio's valuable film library and recent theatrical successes as key drivers for a potential bidding war.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund ($XLE) is trending as energy bulls react to escalating geopolitical tensions in the Middle East and concerns over Strait of Hormuz logistics. Community sentiment is deeply divided between traders playing volatile swings based on war headlines and those betting on a long-term structural supply deficit in global energy markets.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is currently drawing significant community attention as investors anticipate the commercial scaling of its FDA-approved gene therapy, ZEVASKYN, following recent regulatory milestones and the activation of new qualified treatment centers. The stock is a primary focus of discussion due to a potential short squeeze setup, characterized by high short interest and institutional accumulation, while the community remains hyper-focused on the company's ability to hit profitability targets and execute on its manufacturing capacity.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors speculate on potential oncology acquisitions to offset the looming patent cliff for its flagship cancer drug, Keytruda. Community discussion is focused on the company's M&A strategy, with biotech names like Sellas Life Sciences and Inhibrx frequently cited as potential buyout targets for Merck's pipeline expansion.

GLOBALFOUNDRIES, Inc. provides foundry services and manufactures semiconductors. It offers global shuttle, mask, post-fab and turnkey services. The company was founded on October 7, 2008 and is headquartered in Malta, NY.

GlobalFoundries Inc

GlobalFoundries is currently generating investor interest as a vital player in the U.S. semiconductor reshoring and AI infrastructure narrative, driven by its specialized manufacturing capabilities and government-backed quantum initiatives. The community remains focused on the company's potential to scale alongside next-generation technologies, though some discussions highlight concerns regarding liquidity overhangs from major block sales.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF is attracting attention as investors lean into broad-market index funds to navigate market volatility and long-term uncertainty. The community is actively discussing the ETF as a core "set-it-and-forget-it" asset that offers exposure to the entire U.S. economy while providing a resilient hedge against the high-stakes speculation and volatility seen in individual tech and AI-focused stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Credicorp (BAP) Outperforming Other Finance Stocks This Year?

Here is how Credicorp (BAP) and Citigroup (C) have performed compared to their sector so far this year.

Is Banner (BANR) Stock Outpacing Its Finance Peers This Year?

Here is how Banner (BANR) and Credicorp (BAP) have performed compared to their sector so far this year.

BofA Lifts PT on Credicorp (BAP) - Here's Why

BofA Lifts PT on Credicorp (BAP) - Here's Why...

Here's How Much $100 Invested In Credicorp 5 Years Ago Would Be Worth Today

Credicorp (NYSE:BAP) has outperformed the market over the past 5 years by 14.29% on an annualized basis producing an average annual return of 26.06%. Currently, Credicorp has a market capitalization of $30.23 billion.read more...

Credicorp (BAP) Upgraded to Buy: Here's What You Should Know

Credicorp (BAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Credicorp (BAP) is a Great Momentum Stock: Should You Buy?

Does Credicorp (BAP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Credicorp (BAP) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Credicorp (BAP) have what it takes? Let's find out.

Are Finance Stocks Lagging  Credicorp (BAP) This Year?

Here is how Credicorp (BAP) and American Tower (AMT) have performed compared to their sector so far this year.

Why Credicorp (BAP) is a Top Dividend Stock for Your Portfolio

BAP or CMWAY: Which Is the Better Value Stock Right Now?

BAP vs. CMWAY: Which Stock Is the Better Value Option?

Credicorp Ltd. operates as a holding company, which engages in the provision of financial services. It operates through the following segments: Universal Banking; Microfinance; Insurance and Pensions; and Investment Banking and Wealth Management. The Universal Banking segment focuses on lending and investment services. The Microfinance segment consists of subsidiaries offering commercial banking activities and specialized financial services to support small and micro business clients. The Insurance and Pensions segment offers insurance products for property and casualty, life insurance business, and corporate health insurance and medical services. The Investment Banking and Wealth Management segment comprises of asset management, capital markets, corporate finance, and wealth management business units. The company was founded on August 17, 1995 and is headquartered in Lima, Peru.

Credicorp Ltd

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$390.58
Prev Close	$387.44
Open	$382.00
Dividend Yield	5.04%
50-Day Moving Average	$357.44
Beta	0.73
Avg. Volume	624,501.83
PE Ratio	15.00

52-Week High	$403.30
52-Week Low	$225.50
Market Capitalization	$31.06B
EPS (Annual)	$24.46
Price to Book	2.71
Revenue Per Employee	$156,703.53

Feed

News

Sentiment

Earnings

Fundamentals

Info

BAPCredicorp Ltd

Latest BAP News